Blood Biomarkers Predict 10-Year Clinical Outcomes in Adult Patients With Congenital Heart Disease
Authors' conclusion
Blood biomarkers have prognostic value in ACHD. NT-proBNP improves risk prediction and is able to identify low-risk patients.
Study context
- Population
- Adults with moderate or complex congenital heart disease (median age 32.5 years, 42% female, 90% NYHA I)
- Participants
- 602 adults
- Outcome
- All-cause mortality
- Follow-up
- Median 10.1 years
Methodological detailsobservational
- Observational
Main finding
As reported in the abstract
Deaths
41
6.8%
Multibiomarker model: only N-terminal pro-brain natriuretic peptide (NT-proBNP) remained associated with mortality, standardized HR
2.74
95% CI 2.01–3.74
NT-proBNP improved C-statistic of clinical prediction model
0.85-0.92
Observational data: associations, not effects.
Secondary outcomes
Heart failure · median follow-up 10.1 years
- Developed HF
- 81 (13.5%)
- 10-year HF-free survival with NT-proBNP <76 ng/L
- 98.5%
Abnormal biomarker levels at baseline
- Patients with abnormal biomarker levels
- 424 (70.4%)
Original publication
Blood Biomarkers Predict 10-Year Clinical Outcomes in Adult Patients With Congenital Heart Disease. JACC Adv. Published 27 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →